Advanced Pancreatic Cancer Clinical Trial
Official title:
A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer
This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.
This study is a prospective, open-label, single-arm, exploratory clinical study. Recruited 20 subjects who met the inclusion criteria and received Endostar+Envofolimab+Nab-paclitaxel/Gemcitabine (AG regimen) chemotherapy according to the study plan. Treatment duration and dose can be adjusted according to patient tolerance until disease progression or intolerable toxicity, or other conditions determined by the investigator. During the trial, the efficacy indicators and safety indicators were observed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT03662035 -
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
| Recruiting |
NCT06111274 -
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04137536 -
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT04617067 -
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
| Recruiting |
NCT04104672 -
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05100329 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02101580 -
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06329947 -
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
|
Phase 2 | |
| Recruiting |
NCT02135822 -
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04803851 -
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03415802 -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05162118 -
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04643405 -
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03889795 -
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01303172 -
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06422156 -
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04931381 -
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
|
Phase 3 |